TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30175123

Group type: EXPERIMENTAL
Intervention: Intravitreal dexamethasone implant (Ozurdex, Allergan)
Number of subjects: 26
Study: 30175246

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30175268

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study: 30176179

Group type: EXPERIMENTAL
Intervention: Icatibant
Number of subjects: 685
Study: 30176673

Group type: EXPERIMENTAL
Intervention: Spironolactone plus patiromer
Number of subjects: 146

Group type: COMPARATOR
Intervention: Spironolactone plus placebo
Number of subjects: 146
Study: 30176833

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Radiotherapy and hormonal therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Healthy post-menopausal women
Number of subjects: 75
Study: 30176875

Group type: EXPERIMENTAL
Intervention: Autologous bone marrow concentrate (BMC) and platelet products injection
Number of subjects: 29
Study: 30176878

Group type: EXPERIMENTAL
Intervention: Iconic Therapy
Number of subjects: 72

Group type: COMPARATOR
Intervention: Structured Support Therapy
Number of subjects: 72
Study: 30176893

Group type: EXPERIMENTAL
Intervention: Very Low Calorie Diet (VLCD)
Number of subjects: 10
Study: 30176943

Group type: EXPERIMENTAL
Intervention: Progressive early passive and active movement program
Number of subjects: 100

Group type: COMPARATOR
Intervention: Limited early passive movement program (usual care)
Number of subjects: 100
Study: 30176976

Group type: EXPERIMENTAL
Intervention: Positive Airway Pressure (PAP) therapy adherence (h/night)
Number of subjects: 252
Study: 30177021

Group type: EXPERIMENTAL
Intervention: Fostamatinib (an oral prodrug SYK inhibitor)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30177258

Group type: EXPERIMENTAL
Intervention: Paediatric healthcare workers
Number of subjects: 65

Group type: COMPARATOR
Intervention: Non-healthcare workers
Number of subjects: 65

Group type: COMPARATOR
Intervention: Infants
Number of subjects: 65

Group type: COMPARATOR
Intervention: Children
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 65

Group type: COMPARATOR
Intervention: T-cells
Number of subjects: 65
Study: 30177273

Group type: EXPERIMENTAL
Intervention: Women with subclinical cardiac disease
Number of subjects: 581

Group type: EXPERIMENTAL
Intervention: Men with subclinical cardiac disease
Number of subjects: 581
Study: 30177353

Group type: EXPERIMENTAL
Intervention: Infants with colic (37 infants)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Breast milk, formula, or breast + formula feeding in infants with colic
Number of subjects: 65

Group type: COMPARATOR
Intervention: Noncolicky infants (28 infants)
Number of subjects: 65
Study: 30177423

Group type: EXPERIMENTAL
Intervention: Sentry bioconvertible inferior vena cava (IVC) filter
Number of subjects: 129
Study: 30178032

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel (125 mg/m2) plus gemcitabine (1000 mg/m2) administered on days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxic effects.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel plus gemcitabine regimen.
Number of subjects: 74
Study: 30178312

Group type: EXPERIMENTAL
Intervention: Arg16Gly heterozygous group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Homozygous G mutant
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Gln27Glu C wild group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Gln27Glu G mutant group
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Heterozygous Arg16Gly and Gln27Glu
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Homozygous wild and mutant
Number of subjects: 58
Study: 30178481

Group type: EXPERIMENTAL
Intervention: CTL019 infusion
Number of subjects: 51
Study: 30178528

Group type: EXPERIMENTAL
Intervention: Experimental drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30178605

Group type: EXPERIMENTAL
Intervention: 3D transperineal ultrasound
Number of subjects: 57

Group type: COMPARATOR
Intervention: Foley catheter
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Agreement assessment
Number of subjects: 57
Study: 30179569

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) 1.8 mg/kg once every 3 weeks followed by six cycles of AVD chemotherapy and four consolidative doses of Bv
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin (Bv) and AVD chemotherapy
Number of subjects: 48
Study: 30180050

Group type: EXPERIMENTAL
Intervention: Uterosacral ligament suspension (USLS) with a size 'small' titanium vascular clip applied to the base of each suture.
Number of subjects: 15
Study: 30180407

Group type: EXPERIMENTAL
Intervention: Red blood cell transfusion
Number of subjects: 0
Study: 30180831

Group type: EXPERIMENTAL
Intervention: RP intervention
Number of subjects: 290

Group type: COMPARATOR
Intervention: Standard care control
Number of subjects: 290
Study: 30180845

Group type: EXPERIMENTAL
Intervention: Contraceptive communication reported by women
Number of subjects: 867

Group type: EXPERIMENTAL
Intervention: Contraceptive use reported by women
Number of subjects: 867

Group type: COMPARATOR
Intervention: Contraceptive communication reported by husbands
Number of subjects: 867

Group type: COMPARATOR
Intervention: Contraceptive use reported by husbands
Number of subjects: 867
Study: 30180867

Group type: EXPERIMENTAL
Intervention: Single SBRT fraction of 19 Gy to the whole prostate gland with urethra-sparing (17 Gy)
Number of subjects: 0
Study: 30180873

Group type: EXPERIMENTAL
Intervention: (1,3)-β-D-glucan (BDG) group
Number of subjects: 312

Group type: COMPARATOR
Intervention: Standard care group
Number of subjects: 312
Study: 30180887

Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC) consisting of four 5-min cycles of limb ischemia and reperfusion after induction of anesthesia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 0
Study: 30180909

Group type: EXPERIMENTAL
Intervention: BIS neurofeedback intervention
Number of subjects: 10
Study: 30180944

Group type: EXPERIMENTAL
Intervention: NKG2D CAR T cells infused fresh after a 9-day process
Number of subjects: 0
Study: 30181045

Group type: EXPERIMENTAL
Intervention: Double-dose (DD) influenza vaccine (30 µg antigen)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Standard-dose (SD) influenza vaccine (15 µg antigen)
Number of subjects: 79
Study: 30181173

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus rituximab (LR)
Number of subjects: 38
Study: 30181172

Group type: EXPERIMENTAL
Intervention: Siltuximab (or tocilizumab if siltuximab is not available) with or without corticosteroids
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Adjuvant combination chemotherapy
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Additional agents tailored by disease severity
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Response criteria
Number of subjects: 344
Study: 30181185

Group type: EXPERIMENTAL
Intervention: Violet LED treatment (405 nm)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Violet LED + 35% carbamide peroxide
Number of subjects: 80

Group type: COMPARATOR
Intervention: 35% hydrogen peroxide (gold standard)
Number of subjects: 80
Study: 30181315

Group type: EXPERIMENTAL
Intervention: IBM Watson for Oncology (WFO) recommendations
Number of subjects: 362
Study: 30181415

Group type: EXPERIMENTAL
Intervention: Targeted therapeutics against the RAS/RAF/MEK/ERK pathway
Number of subjects: 0
Study: 30181780

Group type: EXPERIMENTAL
Intervention: Peginterferon β-1a every 2 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Peginterferon β-1a every 4 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall NEDA
Number of subjects: 0
Study: 30181874

Group type: EXPERIMENTAL
Intervention: WISE intervention (nutrition education)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Direct assessment of fidelity
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Indirect assessment of fidelity
Number of subjects: 49
Study: 30182209

Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy for mCRC
Number of subjects: 756

Group type: EXPERIMENTAL
Intervention: Metformin treatment among diabetic patients
Number of subjects: 756
Study: 30183115

Group type: EXPERIMENTAL
Intervention: Higher driving pressure (ΔP) measured at ICU admission or 24 hours later
Number of subjects: 221
Study: 30184299

Group type: EXPERIMENTAL
Intervention: Progesterone (200 mg twice daily by vaginal suppository) during add-back phase
Number of subjects: 37

Group type: COMPARATOR
Intervention: Gonadal suppression induced by leuprolide acetate (3.75 mg IM monthly)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no PMDD)
Number of subjects: 37
Study: 30184559

Group type: EXPERIMENTAL
Intervention: EHR clinical decision support (CDS) tool for TBI prediction
Number of subjects: 38
Study: 30185117

Group type: EXPERIMENTAL
Intervention: Extensive intraperitoneal lavage (EIPL)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control (no EIPL)
Number of subjects: 27
Study: 30185165

Group type: EXPERIMENTAL
Intervention: CareToy revised (CT-R) intervention
Number of subjects: 42

Group type: COMPARATOR
Intervention: Infant Massage (IM) intervention
Number of subjects: 42
Study: 30185213

Group type: EXPERIMENTAL
Intervention: Higher baseline ventricular size with low cognitive reserve panel (CR-P) in men
Number of subjects: 723

Group type: EXPERIMENTAL
Intervention: Higher baseline ventricular size with low cognitive reserve panel (CR-P) in women
Number of subjects: 723
Study: 30185228

Group type: EXPERIMENTAL
Intervention: pictilisib (GDC-0941) plus paclitaxel (90 mg/m²)
Number of subjects: 69
Study: 30185407

Group type: COMPARATOR
Intervention: Center-near multifocal design contact lens in the more hyperopic eye
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-vision contact lens in the fellow eye if required
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Center-near multifocal design contact lenses in each eye
Number of subjects: 0

Group type: COMPARATOR
Intervention: Natural progression without any intervention
Number of subjects: 0
Study: 30185431

Group type: EXPERIMENTAL
Intervention: Ruxolitinib (RUX) 2 times per day continuously in 28-day cycles for the first 3 cycles
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azacitidine (AZA) 25 mg/m2
Number of subjects: 0
Study: 30186045

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 500
Study: 30186323

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy Controls
Number of subjects: 0
Study: 30186623

Group type: EXPERIMENTAL
Intervention: Fimasartan (Kanarb), switched to after 8 weeks of treatment
Number of subjects: 12244
Study: 30187270

Group type: EXPERIMENTAL
Intervention: High-flow nasal oxygen therapy (HFNT)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Noninvasive ventilation (NIV)
Number of subjects: 15
Study: 30187421

Group type: EXPERIMENTAL
Intervention: Mentorship programs in bariatric surgery
Number of subjects: 293
Study: 30187599

Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a 180 μg/wk added to ongoing nucleos(t)ide analogue therapy
Number of subjects: 70
Study: 30188978

Group type: EXPERIMENTAL
Intervention: Allometric miltefosine dosing for 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Linear miltefosine dosing (2.5 mg/kg/day for 28 days)
Number of subjects: 30
Study: 30189049

Group type: EXPERIMENTAL
Intervention: Onclarity HPV testing
Number of subjects: 1960

Group type: COMPARATOR
Intervention: Hybrid Capture 2 (HC2)
Number of subjects: 1960

Group type: EXPERIMENTAL
Intervention: HPV genotyping
Number of subjects: 1960
Study: 30189345

Group type: EXPERIMENTAL
Intervention: 24 IU intranasal oxytocin
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 30189858

Group type: EXPERIMENTAL
Intervention: Multi-modal MRI techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical assessment and multi-modal MR imaging examination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Imaging features acquisition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical information collection
Number of subjects: 0
Study: 30189902

Group type: EXPERIMENTAL
Intervention: Enzalutamide
Number of subjects: 662

Group type: COMPARATOR
Intervention: Bicalutamide
Number of subjects: 662
Study: 30189911

Group type: EXPERIMENTAL
Intervention: Active 6-7 hours/week
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Sometimes seeking shade
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Rarely/never seeking shade
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Using a hat rarely/never (in school children)
Number of subjects: 130
Study: 30190005

Group type: EXPERIMENTAL
Intervention: ART
Number of subjects: 54
Study: 30190030

Group type: EXPERIMENTAL
Intervention: Symptom-focused assessment (National Institute for Health and Care Excellence guidelines)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: Risk-based assessment (American College of Cardiology/American Heart Association and European Society of Cardiology guidelines)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: Intermediate-high-risk groups (compared to low-risk groups)
Number of subjects: 13773

Group type: COMPARATOR
Intervention: All guidelines
Number of subjects: 13773
Study: 30190041

Group type: EXPERIMENTAL
Intervention: Sleep quality assessed using the Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Daytime sleepiness assessed using the Epworth Sleepiness Scale (ESS)
Number of subjects: 267
Study: 30190271

Group type: EXPERIMENTAL
Intervention: Nasal samples from the AR group
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Th2 scores in the nose and bronchi
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Th17 scores
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Nasal cells
Number of subjects: 39
Study: 30190299

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg once daily for the first 3 weeks of each 4-week cycle
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Regorafenib-related treatment-emergent adverse events (TEAEs)
Number of subjects: 2872

Group type: EXPERIMENTAL
Intervention: Laboratory toxicities
Number of subjects: 2872
Study: 30190302

Group type: EXPERIMENTAL
Intervention: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib (initially at 5 mg b.i.d. and escalated to a maximum of 10 mg b.i.d.)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: TRC105 (8 mg/kg and then 10 mg/kg weekly) in combination with axitinib
Number of subjects: 18
Study: 30190681

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 30191053

Group type: EXPERIMENTAL
Intervention: Hepatic intra-arterial chemotherapy (IACHT) with Epirubicin-Cisplatin and systemic chemotherapy (SCHT) with Capecitabine or 5-fluorouracil, followed by gemcitabine-based maintenance therapy.
Number of subjects: 145
Study: 30191097

Group type: EXPERIMENTAL
Intervention: Alert/advice (n=198)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Advice-only (n=185)
Number of subjects: 582

Group type: COMPARATOR
Intervention: Control (n=199)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Total sample (N=543)
Number of subjects: 582

Group type: EXPERIMENTAL
Intervention: Follow-up (n=377) after 52 weeks
Number of subjects: 582
Study: 30191144

Group type: EXPERIMENTAL
Intervention: Integrated and person-centered interventions
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Descriptive studies
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Knowledge-to-Action Framework and Complexity Model
Number of subjects: 0
Study: 30191465

Group type: EXPERIMENTAL
Intervention: Denosumab
Number of subjects: 600
Study: 30191464

Group type: EXPERIMENTAL
Intervention: UMEC 62.5 µg + ICS/LABA
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Placebo + ICS/LABA
Number of subjects: 1637
Study: 30191502

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 280

Group type: COMPARATOR
Intervention: Behavioral/pharmacological treatment
Number of subjects: 280
Study: 30191523

Group type: EXPERIMENTAL
Intervention: Ketoconazole 400 mg orally three times daily plus hydrocortisone (20 mg in the morning and 10 mg at night) and lenalidomide 25 mg orally daily for 21 days in a 28-day cycle and aspirin 75 mg daily
Number of subjects: 34
Study: 30191864

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a dose of 40 Gy in 5 fractions of 8 Gy
Number of subjects: 309

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 309
Study: 30192444

Group type: EXPERIMENTAL
Intervention: Transdermal nicotine (maximum dose of 21.0 mg/d, applied daily with dose escalation)
Number of subjects: 15
Study: 30192949

Group type: EXPERIMENTAL
Intervention: IL-13 levels
Number of subjects: 277

Group type: EXPERIMENTAL
Intervention: IFN-γ/IL-13 ratio and IL-10 levels
Number of subjects: 277
Study: 30193554

Group type: EXPERIMENTAL
Intervention: Combined exercise training (CET)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control
Number of subjects: 30
Study: 30194205

Group type: EXPERIMENTAL
Intervention: 18 Gy
Number of subjects: 199

Group type: COMPARATOR
Intervention: 21 Gy
Number of subjects: 199
Study: 30194585

Group type: EXPERIMENTAL
Intervention: Single 40 mg oral dose of imarikiren
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal renal or hepatic function (control group)
Number of subjects: 0
Study: 30194931

Group type: EXPERIMENTAL
Intervention: Gene therapy using viral vectors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgical techniques for gene therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patient selection and target zone planning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Viral vectors
Number of subjects: 0
Study: 30195193

Group type: EXPERIMENTAL
Intervention: hrHPV testing on vaginal self-samples
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: hrHPV testing on first-void urine samples
Number of subjects: 500

Group type: COMPARATOR
Intervention: hrHPV testing on matched clinician-taken samples
Number of subjects: 500
Study: 30195661

Group type: EXPERIMENTAL
Intervention: Brief Behavioral Treatment for Insomnia (BBTi)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Self-Monitoring Control (SMC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: BBTi and SMC
Number of subjects: 0
Study: 30196791

Group type: EXPERIMENTAL
Intervention: Insertable cardiac monitors
Number of subjects: 441
Study: 30196853

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e9 vg/eye
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e10 vg/eye
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector by intravitreal injection at a dosage of 1e11 vg/eye
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: AAV8-RS1 gene vector
Number of subjects: 9
Study: 30197098

Group type: EXPERIMENTAL
Intervention: Darolutamide in combination with androgen deprivation therapy (ADT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Darolutamide in combination with ADT
Number of subjects: 0

Group type: COMPARATOR
Intervention: Darolutamide versus placebo in addition to standard ADT and docetaxel
Number of subjects: 0
Study: 30197186

Group type: EXPERIMENTAL
Intervention: Motivational phone call by a physician from the screening organisation
Number of subjects: 56

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 56
Study: 30197280

Group type: EXPERIMENTAL
Intervention: Complete cytoreductive surgery
Number of subjects: 796
Study: 30197287

Group type: EXPERIMENTAL
Intervention: Asymptomatic carotid artery stenosis (CS) ≥ 50%
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: CS severity categories
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: CS of 90-99%
Number of subjects: 2813

Group type: EXPERIMENTAL
Intervention: Occluded internal carotid artery
Number of subjects: 2813
Study: 30197540

Group type: EXPERIMENTAL
Intervention: Directly mailed self-sampling kit
Number of subjects: 9791

Group type: EXPERIMENTAL
Intervention: Opt-in self-sampling kit
Number of subjects: 9791

Group type: COMPARATOR
Intervention: Control group (standard second reminder for cytology screening)
Number of subjects: 9791
Study: 30197625

Group type: EXPERIMENTAL
Intervention: Bariatric-induced weight loss
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 30198055

Group type: EXPERIMENTAL
Intervention: Premorbid traumatic brain injury (TBI)
Number of subjects: 505

Group type: COMPARATOR
Intervention: Control group (no premorbid TBI)
Number of subjects: 505
Study: 30198325

Group type: EXPERIMENTAL
Intervention: Probiotic mixture for 4 months
Number of subjects: 45
Study: 30198934

Group type: EXPERIMENTAL
Intervention: Alfentanil 10 µg·kg(-1)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 20
Study: 30199311

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFOX-4
Number of subjects: 393

Group type: COMPARATOR
Intervention: FOLFOX-4
Number of subjects: 393
Study: 30199512

Group type: EXPERIMENTAL
Intervention: MILD procedure
Number of subjects: 274

Group type: COMPARATOR
Intervention: Epidural steroid injections
Number of subjects: 274
Study: 30199593

Group type: EXPERIMENTAL
Intervention: All-oral DAA combinations
Number of subjects: 848
Study: 30200905

Group type: EXPERIMENTAL
Intervention: HIV self-testing (HIVST) conducted by MSM, either finger prick or oral fluid, without assistance from a trained counselor
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Finger prick HIV self-testing
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Oral fluid HIV self-testing
Number of subjects: 27
Study: 30200969

Group type: EXPERIMENTAL
Intervention: Structured peer support in PMTCT (Mother Mentor study)
Number of subjects: 36
Study: 30200977

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound measurements in healthy volunteers
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Transcranial Doppler ultrasound measurements in patients with symptomatic carotid artery stenosis
Number of subjects: 40